指南与共识精神分裂症与精神病性障碍

难治性精神分裂症:TRRIP工作组关于诊断与术语的共识指南

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
指南 / 共识 · Am J Psychiatry · 2016-12-06

该共识指南针对精神分裂症治疗抵抗与治疗反应定义不一致的问题,系统综述了42项随机抗精神病药临床试验,发现仅5%研究使用相同标准。工作组通过多阶段混合方法制定共识操作标准,明确治疗抵抗、充分治疗和治疗反应的定义,为研究与临床转化提供基准。

要点

  • 现有难治性精神分裂症定义差异大,仅5%研究使用相同标准。
  • 共识提出治疗抵抗的最低与最佳标准,涵盖症状、功能、既往治疗、依从性等。
  • 共识操作化定义旨在统一研究与临床报告,提供可比较的基准。

核心结论

  • 当前精神分裂症治疗抵抗定义存在显著差异,共识指南提供了操作化标准以统一诊断与报告。

研究设计与样本

  • 系统综述纳入42项难治性精神分裂症随机抗精神病药临床试验,并通过多阶段混合方法、在线调查和共识会议制定标准。

主要发现

  • 共识别2808项研究,42项符合纳入标准,其中21项(50%)未提供操作化标准。
  • 其余研究在症状严重度、既往治疗时长和抗精神病药剂量阈值上差异显著,仅2项研究(5%)使用相同标准。

关键数值与推荐

  • 共识组确定最低与最佳标准,原则包括:当前症状持续时间和严重度由标准化评定量表确定。
  • 功能损害为中度或更差。
  • 既往治疗包含至少两种不同抗精神病药试验,每种有最低时长和剂量要求。
  • 系统监测依从性并满足最低依从标准。
  • 理想情况下至少一次前瞻性治疗试验。

临床怎么用

  • 临床可依据共识标准评估难治性精神分裂症,统一记录治疗抵抗、充分治疗和治疗反应。

局限性

  • 系统综述仅纳入随机抗精神病药临床试验,可能未覆盖所有研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. METHOD: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus. RESULTS: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting of minimum adherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients. CONCLUSIONS: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2016. PMID: 27919182. doi:10.1176/appi.ajp.2016.16050503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。